Indian drug makers likely to stay competitive despite planned tariffs

DRREDDY

Indian drugmakers, including

are confident about maintaining competitiveness in the generic drugs market despite potential U.S. tariffs on pharmaceutical imports. MD, GV Prasad, stated that Indian firms are awaiting more details on the tariffs but emphasized that shifting pharmaceutical production to the U.S. is impractical and would increase costs, keeping Indian and Chinese companies competitive.